Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous <scp>FOLFOX</scp> and bevacizumab for patients with unresectable colorectal liver‐limited metastasis

Abstract

The simultaneous administration of mFOLFOX6 (with or without bevacizumab) and DEBIRI through the hepatic artery (FOLFOX-DEBIRI) is safe and does not cause treatment delays or increase the systemic toxicity of chemotherapy. This strategy leads to improved overall response rates, improved hepatic progression-free survival, and more durable overall progression-free survival in patients downsized to resection.